Aurobindo, Lannett deal requires divestiture of four drug products, US FTC says
MLex Summary: Aurobindo Pharma Limited is required to divest four generic drug products to complete its $250 million acquisition of Lannett Company Inc., according to an order released by the US...To view the full article, register now.
Already a subscriber? Click here to view full article